Identification of two atypical PML-RARα transcripts in two patients with acute promyelocytic leukemia

被引:18
|
作者
Barragán, E
Bolufer, P
Martín, G
Cervera, J
Moreno, I
Capote, FJ
Rosique, P
Sanz, MA
机构
[1] Hosp Univ La Fe, Ctr Maternal, Dept Clin Pathol, Mol Biol Lab, Valencia 46009, Spain
[2] Hosp Univ La Fe, Ctr Maternal, Dept Hemathol, Valencia 46009, Spain
[3] Hosp Univ Puerta Mar Cadiz, Dept Hemathol, Cadiz 11009, Spain
[4] Hosp Univ Virgen Arrixaca, Dept Hemathol, Murcia 30120, Spain
关键词
acute promyclocytic leukemia; PML-RAR alpha; RAR alpha-PML;
D O I
10.1016/S0145-2126(01)00158-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We identified two patients with atypical PML-RARalpha rearrangements, 53 and 13 base pairs longer than the typical bcrl transcript. Sequence analysis revealed a new PML breakpoint at the end of exon 7a in patient 1, and a PML exon 6 breakpoint in patient 2, with an insertion of 35 nucleotides of RARalpha intron 2. Patient I did not express RARalpha,-PML and patient 2 showed the RARalpha-PML transcript, which corresponded to the typical bcrl. These results emphasize on the relevance of the correct identification of atypical PML-RARalpha rearrangements because of the potential implications in leukemogenesis, in the response to treatment, and for the correct monitoring of minimal residual disease. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:439 / 442
页数:4
相关论文
共 50 条
  • [11] Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia
    Iaccarino, Licia
    Divona, Mariadomenica
    Ottone, Tiziana
    Cicconi, Laura
    Lavorgna, Serena
    Ciardi, Claudia
    Alfonso, Valentina
    Travaglini, Serena
    Facchini, Luca
    Cimino, Giuseppe
    Di Bona, Eros
    Voso, Maria Teresa
    Lo-Coco, Francesco
    GENES CHROMOSOMES & CANCER, 2019, 58 (01): : 60 - 65
  • [12] A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia
    Pollock, JL
    Westervelt, P
    Kurichety, AK
    Pelicci, PG
    Grisolano, JL
    Ley, TJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) : 15103 - 15108
  • [13] Development and validation of a droplet digital PCR assay for the evaluation of PML-RARα fusion transcripts in acute promyelocytic leukemia
    Jiang, Xi-wen
    Chen, Si-ze
    Zhu, Xiao-ya
    Xu, Xiao-xie
    Liu, Yue
    MOLECULAR AND CELLULAR PROBES, 2020, 53
  • [14] Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia
    J Román
    C Martín
    A Torres
    MA Jiménez
    P Andrés
    R Flores
    MJ de la Torre
    J Sánchez
    J Serrano
    M Falcón
    Bone Marrow Transplantation, 1997, 19 : 679 - 683
  • [15] MiRNA transcription is regulated by the PML-RARα oncoprotein in acute promyelocytic leukemia.
    Nigten, Jeannet
    Knops, Ruth
    Nikoloski, Gorica
    de Witte, Theo M.
    van der Reijden, Bert A.
    Jansen, Joop H.
    BLOOD, 2006, 108 (11) : 129B - 129B
  • [16] PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
    Ohnishi, Kazunori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 313 - 317
  • [17] Quantitation of PML-RARα transcripts in APL patients
    Tobal, K
    LEUKEMIA, 2000, 14 (08) : 1530 - 1531
  • [18] Sentrinization and ubiquitination differentially regulate the fate of PML and PML-RARα in acute promyelocytic leukemia.
    Kamitani, T
    Yeh, ETH
    BLOOD, 1998, 92 (10) : 404A - 404A
  • [19] Using quantification of the PML-RARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia
    Santamaria, Carlos
    Carmen Chillon, Maria
    Fernandez, Carina
    Martin-Jimenez, Patricia
    Balanzategui, Ana
    Garcia Sanz, Ramon
    San Miguel, Jesus F.
    Gonzalez, Marcos-Gonzalez
    HAEMATOLOGICA, 2007, 92 (03) : 315 - 322
  • [20] PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
    Kazunori Ohnishi
    International Journal of Clinical Oncology, 2007, 12 : 313 - 317